The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Jeff Sharman, MD, Medical Director at US Oncology, will present "Exploration of Barriers and Solutions for Activating and Sustaining Research Programs in Nonacademic
The US Food and Drug Administration has approved lisocabtagene maraleucel (liso-cel; Breyanzi), a CD19-directed CAR T-cell therapy, for adult patients with relapsed or
Krish Patel presents at 1:15 pm CST on April 15, 2026, on building partnerships between community and academic centers.
The United States Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca), a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, for adults with
Held on March 18, 2026, from 12:30–1:00 PM CST with Jeffrey Matous presenting "Managing Access to Novel Agents in the Community Setting."
Manali Kamdar, MD, will present at 4:30–5 pm on January 20, 2026, on “Expanding access to CAR T-cell therapy outside academic centers.”
In this panel discussion at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Elias Jabbour, MD, leukemia professor at
The US Food and Drug Administration (FDA) approved updates to the prescribing information for ciltacabtagene autoleucel (CARVYKTI). The agency added a boxed warning
The European Commission expanded approval of the CD19-directed chimeric antigen receptor T-cell therapy lisocabtagene maraleucel (liso-cel; Breyanzi®) in patients with relapsed or refractory
In this video interview with SOHO Insider Al-Ola A. Abdallah, MD, associate professor and director of the Plasma Cell Disorder program at the
